Role of the endocannabinoid system in depression and suicide
Open Access
- 31 October 2006
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 27 (10), 539-545
- https://doi.org/10.1016/j.tips.2006.08.006
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disordersTrends in Pharmacological Sciences, 2005
- Identification and Functional Characterization of Brainstem Cannabinoid CB 2 ReceptorsScience, 2005
- A60 SURINABANT, A NEW CB1 RECEPTOR ANTAGONIST, DISPLAYS EFFICACY IN ANIMAL MODELS OF ATTENTION DEFICIT/HYPERACTIVITY DISORDERBehavioural Pharmacology, 2005
- Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disordersLife Sciences, 2005
- Downregulation of Endocannabinoid Signaling in the Hippocampus Following Chronic Unpredictable StressNeuropsychopharmacology, 2004
- The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout miceLife Sciences, 2004
- Depression, Negative Self-Image, and Suicidal Attempts as Effects of Substance Use and Substance DependenceJournal of Addictive Diseases, 2004
- Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victimsMolecular Psychiatry, 2004
- Neurobiology of suicidal behaviourNature Reviews Neuroscience, 2003
- The cannabinoid receptorsProstaglandins & Other Lipid Mediators, 2002